Supporting Information Open Port Probe Sampling Interface for the Direct Coupling of Biocompatible Solid-Phase Microextraction to Atmospheric Pressure Ionization Mass Spectrometry Germán Augusto Gómez-Ríos ±, Chang Liu*, Marcos Tascon ±, Nathaly Reyes-Garcés ±, Don W. Arnold, Thomas R. Covey, Janusz Pawliszyn* ± ± Department of Chemistry, University of Waterloo, Waterloo, Ontario N2L 3G1, Canada SCIEX, 71 Four Valley Drive, Concord, Ontario L4K 4V8, Canada SCIEX, 1201 Radio Road, Redwood City, CA 94065 These authors contributed equally *Corresponding author: Tel.: +1 519 888 4641; fax: +1 519 746 0435. E-mail address: Janusz@uwaterloo.ca (J. P.). Tel: +1 289 982 2319; fax: +1 905 660 2623. E-mail: chang.liu@sciex.com (C. L.). S1
Summary This file contains additional information regarding procedures and data described in the main manuscript. The supporting information herein includes the following sections: materials and supplies; setup of the DMS-MS system; MRM parameters; figures of merit for analysis of urine; and pictures of the experimental setup. DMS-MS system for clenbuterol analysis A DMS system (SelexION+, SCIEX, Concord, ON) was mounted in the atmospheric region between the sampling orifice of the QTRAP 6500+ (SCIEX) system and its electrospray ionization (ESI) source. The ESI probe was maintained at a voltage of 5500 V. A constant gas flow in the DMS cell was achieved by curtain gas flow (N 2 ; 30 psi, 7.1 L min 1 ) and the primary stage vacuum pumping of the MS system. The temperature of the transport gas in the DMS cell was maintained at 100 C (DMS heater setting of 150 C). For the experiments conducted in this study, the separation voltage (SV) was set at 4000 V, and the compensation voltage (CV) was set at 13.0 V for optimal transmission of clenbuterol and clenbuterol-d 9. S2
Table S1 Manufacturers, LogP, mass spectrometry, and DMS conditions monitored for each analyte. Compound Manufacturer Log P b Parent Fragment DP [V] EP [V] CE [V] CXP[V] SV [V] CV [V] [m/z] [m/z] Buprenorphine Cerilliant a 4.53 468.3 396.2 120 10 55 10 NA NA Buprenorphine-d 4 Cerilliant a - 472.3 400.2 120 10 55 10 NA NA Fentanyl Cerilliant a 3.82 337.3 188.2 120 10 32 10 NA NA Fentanyl-d 5 Cerilliant a - 342.2 188.2 120 10 32 10 NA NA Clenbuterol Cerilliant a 2.33 277.1 203.1 60 10 24 10 4000 13.0 Clenbuterol-d 9 Cerilliant a - 286.1 204.1 60 10 24 10 4000 13.0 a Cerilliant (Round Rock, TX, USA); b Log P, logarithm of its partition coefficient between n-octanol and water (data taken from www.drugbank.ca). Dwell time was 50 ms for all analytes. DP: Declustering potential, EP: Entrance potential, CE: Collision energy, CXP: Collision cell exit potential. All experiments were performed using an SCIEX QTRAP 6500+ MS/MS system with Ion Drive source and Electrospray Ionization (ESI) probe (SCIEX, Concord, Canada). S3
Table S2 MRM 3 conditions for clenbuterol analysis Compound MRM 3 transition CE [V] DP [V] EP[V] Clenbuterol 277.1-203.1-168.1 24 100 10 Clenbuterol d 9 286.1-204.1-169.1 24 100 10 Table S3 Figures of merit for the concomitant analysis of fentanyl and buprenorphine in urine by Bio-SPME-OPP in MRM mode Compound Concentration accuracy (, ± SD) 3 [ng/ml] 40 [ng/ml] 80 [ng/ml] LOD [ng/ml] LOQ [ng/ml] Fentanyl 3.2 ± 0.2 37.2 ± 1.4 83.1 ± 0.2 0.05 0.25 Buprenorphine 2.8 ± 0.1 37.9 ± 0.2 80.4 ± 0.3 0.25 0.50 Table S4 Figures of merit for the analysis of clenbuterol in urine by Bio-SPME OPP-MRM 3 Compound Concentration accuracy (± SD) 0.25 [ng/ml] 2.5 [ng/ml] 75 [ng/ml] LOD [ng/ml] LOQ [ng/ml] Clenbuterol 0.3 ± 0.1 2.5 ± 0.2 73.1 ± 0.8 0.03 0.1 S4
Figure S1 Schematic of the Open-Port-Probe interface used for desorption-ionization of Bio-SPME fibers. All experiments were performed using an SCIEX QTRAP 6500+ MS/MS system with Ion Drive source and Electrospray Ionization (ESI) probe (SCIEX, Concord, Canada). S5
Figure S2 Fentanyl (A) and buprenorphine (B) ion-chronograms signals corresponding to a 5 min extraction at 1500 rpm from 300 µl of pooled urine spiked with 0.05 and 0.5 ng ml -1 of fentanyl and buprenorphine, respectively. Extractions were performed using a 4 mm Bio-SPME mix mode fiber. Figure S3 Ion-chronograms for clenbuterol obtained using (A) MRM (277.1-203.1), (B) MRM 3 (277.1-203.1-168.1) for a double-blank of urine (no standard or internal standard spiked) and (C) MRM 3 (277.1-203.1-168.1) for 0.2 ng/ml clenbuterol spiked in urine. Extraction conditions were 5 min extraction time and 1500 rpm from 300 µl of pooled urine, using a 4 mm Bio- SPME mix mode fiber. S6
Figure S4. Quantitative analysis of urine spiked with clenbuterol (100 pg ml 1 to 100 ng ml 1 ) and its isotopologue [D9] clenbuterol (10 ng ml 1 ). Analyses were performed using SPME-OPP- MRM 3 (m/z 277 259 168). Blue circles represent the obtained accuracy levels (0.25, 2.5, and 75 ng ml 1, respectively). Bars represent the standard deviation of analyses for three replicates with independent fibers S7
Figure S5 Ion-chronograms obtained for clenbuterol obtained using (A) only MRM (277.1-203.1) and (B) DMS and MRM (277.1-203.1) for a double-blank of urine (no-internal standard spiked). Extractions conditions were 5 min extraction time at 1500 rpm from 300 µl of pooled urine, using a 4 mm Bio-SPME mix mode fiber. Figure S6 Ion-chronograms obtained using Bio-SPME-OPP and DMS-MS/MS. Extraction were performed from pooled urine blank (A) and pooled urine spiked with 0.25 ng ml -1 of clenbuterol (B). Extractions conditions were 5 min extraction time at 1500 rpm from 300 µl of pooled urine, using 4 mm Bio-SPME mix mode fiber. S8